Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE (PAR: OSE) presents full CoTikiS results at ECCO 2025
Published by Arron Aatkar, PhD

OSE Immunotherapeutics reported the full induction results from the CoTikiS trial at ECCO 2025 (the 20th congress of the European Crohn’s and Colitis Organisation), as part of the top 10 congress highlights oral plenary session. CoTikiS was a randomised, double-blind, Phase II study assessing the company’s IL-7R monoclonal antibody (mAb) therapy in patients with moderate to severe ulcerative colitis (UC). At ECCO, OSE also presented encouraging preclinical data on the combination of anti-IL-7 receptor with anti-IL-12/23 mAb in chronic colitis.

See here for details on the upcoming webinar: Lusvertikimab and the future of IBD: KOL insights post-ECCO.

Latest

TMT | Comment

Pinewood (LSE: PINE) buys Seez

Industrials | Comment

Metlen (ASE: MYTIL) FY24 Results

Healthcare | Comment

GSK’s (LSE: GSK) five-in-one vaccine approved by the FDA

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free